Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. (ELVN) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
elvn · stock forecast · 7 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$80.00
Consensus
$67.00
+95.8% upside
Low
$59.00
Median: $62 · Last Close: $34.21
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$67.00
95.8% upside
High Target
$80
133.8%
Low Target
$59
72.5%
Current Price
$34.21
as of today
Based on analyst price targets, the ELVN stock price prediction for the next 12 months ranges from $59 to $80. The consensus ELVN price forecast of $67.00 implies 95.8% upside from the current price of $34.21.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $32.50 | ↓ 5.00% |
1-day model range: $32.33–$32.67. Peak: $32.67 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ELVN · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-06-02 | Mizuho | Maintains | Outperform→Outperform |
| 2026-05-08 | Goldman Sachs | Maintains | Buy→Buy |
| 2026-03-26 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-25 | Mizuho | Maintains | Outperform→Outperform |
| 2025-07-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-06-16 | Baird | Maintains | Outperform→Outperform |
| 2025-05-16 | Jones Trading | Maintains | Buy→Buy |
| 2025-05-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-21 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-15 | Baird | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Enliven Therapeutics, Inc. (ELVN) stock. Of the recent 13 rating actions, 0 were upgrades and 0 were downgrades. 7 analysts currently cover ELVN.
Analyst Recommendation Trends
ELVN analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 40.0% YoY
Revenue Next Year
$0M
↓ 16.7% YoY
EPS This Year
$-1.75
EPS Next Year
$-2.38
↑ 36.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast ELVN EPS of $-1.75 for the current fiscal year, based on estimates from 4 analysts. The ELVN revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ELVN stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ELVN price target is $67.00 (+95.8% upside), with an analyst consensus of Buy.
The ELVN short-term stock prediction for tomorrow is $32.50 (-5.00%).
Enliven Therapeutics, Inc. trades on NASDAQ under the ticker ELVN. The ELVN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
ELVN forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month ELVN price target is $67.00, with a high forecast of $80.00 and a low of $59.00. The median price target is shown in the chart above when available. This implies +95.8% potential upside from the current price of $34.21.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.